hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06337591, orgStudyIdInfo id: INRCA_003_2024, briefTitle: Diagnostic Performance of the Vesical Imaging-Reporting and Data System (VI-RADS) in Detecting Muscle-invasive Bladder Tumour (MIBC) in Clinical Practice: Comparison With Transurethral Resection of Bladder Cancer (TURB) and Evaluation of Diagnostic Accuracy According to Tumour Location, acronym: VI-RADS, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-10-15, primaryCompletionDateStruct date: 2024-03-10, completionDateStruct date: 2024-03-10, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Istituto Nazionale di Ricovero e Cura per Anziani, class: OTHER, descriptionModule briefSummary: VI-RADS was an observational, prospective, multicenter, no profit study. The aim of the study was to clarify the clinical validity of the Vesical Imaging-Reporting and Data System (VI-RADS) for the assessment of muscle invasion (MI) status in comparison with transurethral resection of bladder cancer (TURB) and to evaluate the diagnostic accuracy of the score according to the specific tumour location., conditionsModule conditions: Bladder Cancer, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 20, type: ACTUAL, armsInterventionsModule interventions name: VI-RADS, outcomesModule primaryOutcomes measure: Sensitivity of Vescical Imaging-Reporting and Data System (VI-RADS) in predicting muscle-invasive bladder cancer after transurethral resection, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: AOU Hospital, city: Ancona, country: Italy, geoPoint lat: 43.5942, lon: 13.50337, locations facility: IRCCS INRCA Hospital, city: Ancona, country: Italy, geoPoint lat: 43.5942, lon: 13.50337, locations facility: Carlo Urbani Hospital, city: Jesi, country: Italy, geoPoint lat: 43.52142, lon: 13.24368, hasResults: False
protocolSection identificationModule nctId: NCT06337552, orgStudyIdInfo id: MCC-22709, briefTitle: High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial), statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-19, primaryCompletionDateStruct date: 2027-03, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: H. Lee Moffitt Cancer Center and Research Institute, class: OTHER, descriptionModule briefSummary: The purpose of the study is to evaluate the feasibility and acceptability of a dietary intervention (FEED-FF) that includes fermented foods (FF), among locally advanced rectal cancer patients, and to explore whether this diet can improve outcomes in rectal cancer patients receiving chemoradiotherapy (CRT)., conditionsModule conditions: Rectal Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Participants will be randomized to either the FEED-FF Arm or the Standard of Care (SUC) Arm, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: Clincial response will be determined in clinic when patients undergo blinded tumor assessments by standard digital rectal exam, endoscopy, and rectal MRI at baseline and at the end of the intervention., whoMasked: CARE_PROVIDER, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: FEED-FF, interventions name: Standard of Care (SUC), outcomesModule primaryOutcomes measure: Effects of the FEED-FF diet on clinical response to chemoradiation, primaryOutcomes measure: Effects of FEED-FF diet on the gut microbiome, primaryOutcomes measure: Effects of FEED-FF diet on local immune-related biomarkers, primaryOutcomes measure: Effects of FEED-FF diet on quality of life, primaryOutcomes measure: Efficacy of the FEED-FF intervention, primaryOutcomes measure: Feasibility of the FEED-FF intervention, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Moffitt Cancer Center, status: RECRUITING, city: Tampa, state: Florida, zip: 33612, country: United States, contacts name: Stephanie Hogue, role: CONTACT, phone: 813-745-1891, email: Stephanie.Hogue@moffitt.org, contacts name: Doratha (Armen) Byrd, MPH, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Sylvia Crowder, PhD, RDN, LDN, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 27.94752, lon: -82.45843, hasResults: False
protocolSection identificationModule nctId: NCT06337539, orgStudyIdInfo id: PI-23-185, briefTitle: Precision Psychiatry for Depression: Immune Response and Affective Symptoms as Predictors of Response to Antidepressants, acronym: LYMPHODEP, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-07-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Germans Trias i Pujol Hospital, class: OTHER, descriptionModule briefSummary: Objectives: To identify in patients with major depression different peripheral markers of neuroinflammation in relation to affective symptoms (anxiety, depression, irritability), fatigue and cognitive symptoms; and its relationship with the response to antidepressant treatment with selective serotonin reuptake inhibitors (SSRIs).Methodology: This is a prospective observational cohort study in patients with major depression naturally subjected to treatment with SSRIs. For this, 30 patients with major depression attended in the Outpatient Psychiatry Consultations will be selected. All of them will be evaluated at baseline and after 3 months of treatment, collecting demographic and clinical variables, Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) psychiatric diagnoses, psychopathological scales and immunological and biochemical variables. The correlation between immunological markers and affective and cognitive symptoms at baseline, as well as their variation with treatment, will be analyzed. A group of 20 healthy subjects will be used as a control group.Subsequently, a bivariate comparative analysis will be carried out, where the statistically significant or marginally significant variables associated with psychopathological variables will be used to build a multivariate binary logistic regression model., conditionsModule conditions: Depression, conditions: Inflammation, conditions: Antidepressants, conditions: Immunity, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: SSRI, outcomesModule primaryOutcomes measure: Treatment Response, secondaryOutcomes measure: Lymphocyte subpopulations, secondaryOutcomes measure: Biochemical variables, secondaryOutcomes measure: Single-cell CITEseq, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hospital Universitari Germans Trias i Pujol, city: Badalona, state: Catalonia, zip: 08916, country: Spain, geoPoint lat: 41.45004, lon: 2.24741, hasResults: False
protocolSection identificationModule nctId: NCT06337526, orgStudyIdInfo id: IRB-71503, briefTitle: Predicting Pain Exacerbations in Children With Complex Regional Pain Syndrome (CRPS), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, collaborators name: Medeloop.ai, descriptionModule briefSummary: objectives: identify physiologic, dietary, and environment triggers of severe pain exacerbations in children with CRPS., conditionsModule conditions: Complex Regional Pain Syndromes, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Apple Watch v8, outcomesModule primaryOutcomes measure: Change from baseline in pain score, eligibilityModule sex: ALL, minimumAge: 8 Years, maximumAge: 17 Years, stdAges: CHILD, contactsLocationsModule locations facility: Pediatric Pain Clinic, city: Stanford, state: California, zip: 94305, country: United States, geoPoint lat: 37.42411, lon: -122.16608, hasResults: False
protocolSection identificationModule nctId: NCT06337500, orgStudyIdInfo id: 2023/764, briefTitle: Validation of a Making Decision Hybrid (Ecologic and Virtual) Task, acronym: LABLife, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-02-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Centre Hospitalier Universitaire de Besancon, class: OTHER, descriptionModule briefSummary: The aim of this study is to validate a new hybrid (ecological + virtual) decision-making tool. The difference in behavior (risky choices) between the "hybrid" task and the "virtual" task will be evaluated., conditionsModule conditions: Healthy Volunteers, conditions: Behavior and Behavior Mechanisms, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 180, type: ESTIMATED, armsInterventionsModule interventions name: Neurophysiological measure (EEG), interventions name: Survey, outcomesModule primaryOutcomes measure: Validation of the homemade "Lab-Life" interface as a tool for simulating an ecological task with sufficient fidelity, while meeting the conditions required for recording high-quality brain activity using an EEG-HR., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337474, orgStudyIdInfo id: [2023]YLJSA089, briefTitle: An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune Thrombocytopenia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2025-03-30, completionDateStruct date: 2026-03-30, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Changzhou No.2 People's Hospital, class: OTHER, collaborators name: Rui Therapeutics Co., Ltd, descriptionModule briefSummary: A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19 CAR NK cells (KN5501) in patients with refractory immune thrombocytopenia. 9 patients are planned to be enrolled in the dose-escalation trial (9×10\^9 cells, 13.5×10\^9 cells). The primary objective of the study is to evaluation of the safety and feasibility of KN5501 for the treatment of relapsed/refractory B-cell related autoimmune diseases. The secondary objective is to evaluate evaluation of KN5501 for the treatment of refractory immune thrombocytopenia. The exploratory objective is to evaluate expansion, persistence and ability to deplete CD19 positive B cells of KN5501 in patients with refractory immune thrombocytopenia., conditionsModule conditions: Thrombocytopenia Alloimmune, designModule studyType: INTERVENTIONAL, phases: EARLY_PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 9, type: ESTIMATED, armsInterventionsModule interventions name: anti-CD19 CAR NK cells (KN5501), outcomesModule primaryOutcomes measure: Incidence of Dose Limiting Toxicity (DLTs), primaryOutcomes measure: Treatment Emergent Adverse Events (TEAEs), secondaryOutcomes measure: Objective Response Rate of subjects, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337461, orgStudyIdInfo id: CCM1930, briefTitle: Computational mOdelliNg of myoCardial pERfusion to Improve ouTcome Prediction Based on cOronary Artery Stenosis and Atherosclerotic Plaque Burden Assessment by Computed Tomography, acronym: CONCERTO, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-22, primaryCompletionDateStruct date: 2025-05-30, completionDateStruct date: 2025-05-30, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Centro Cardiologico Monzino, class: OTHER, collaborators name: Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, collaborators name: Politecnico di Milano, descriptionModule briefSummary: Detection of coronary stenosis is of utmost importance in identifying vulnerable patients. The combined use of coronary computed tomography angiography at rest (CCTA) and stress myocardial computed tomography perfusion (stress-CTP) provides both anatomic and functional analysis of coronary artery disease (CAD) using a single imaging test. Stress-CTP evaluates myocardial perfusion by measuring myocardial blood flow (MBF) under pharmacologically induced stress conditions. The drawback is that stress-CTP requires additional scanning and administration of an intravenous stressor with an increase in radiation exposure and potential stressor-related side effects. The investigators recently patented a computational model that can reproduce MBF under stress conditions (Italian patent n. 102021000031475 Metodo implementato mediante computer per la simulazione del flusso sanguigno miocardico in condizioni di stress \[Computational method for simulating myocardial blood flow in stress conditions\], half owned by Centro Cardiologico Monzino, half by Politecnico di Milano).On top of this, CCTA can characterize plaque type and identify adverse plaque characteristics. Moreover, biomechanics analysis allows the study of luminal stenosis and stress within the plaque. Finally, radiomics, extracting quantitative features from medical images to create big data and identify novel imaging biomarkers, can be applied to improve the diagnostic accuracy of coronary plaques., conditionsModule conditions: Chronic Coronary Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 400, type: ESTIMATED, outcomesModule primaryOutcomes measure: Development of a computational model to predict MBF avoiding CT stress protocol, secondaryOutcomes measure: Improvement of CAD risk assesment, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Centro Cardiologico Monzino, status: RECRUITING, city: Milan, zip: 20131, country: Italy, contacts name: Chiara Centenaro, role: CONTACT, phone: 0258002031, phoneExt: +39, email: chiara.centenaro@cardiologicomonzino.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06337435, orgStudyIdInfo id: 8223, briefTitle: Using Multi-looped Lingual Retainer to Relief Anterior Mandibular Crowding, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-12-15, primaryCompletionDateStruct date: 2023-07-10, completionDateStruct date: 2024-01-18, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: this study aim to evaluate the multi-looped lingual retainer activated by a new method to relief the anterior crowding, conditionsModule conditions: Crowding of Anterior Mandibular Teeth, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 12, type: ACTUAL, armsInterventionsModule interventions name: multi-looped wire, outcomesModule primaryOutcomes measure: The improvement of lower incisors irregularity using Little Irregularity Index., secondaryOutcomes measure: The stability of lower incisor positioning after ending treatment, eligibilityModule sex: ALL, minimumAge: 16 Years, maximumAge: 25 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: faculty of dentistry Cairo university, city: Cairo, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06337422, orgStudyIdInfo id: BE21-023, briefTitle: Bioequivalence Study of Generic Celecoxib 200 mg Capsules, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09-23, primaryCompletionDateStruct date: 2024-09-27, completionDateStruct date: 2024-10-04, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: International Bio service, class: NETWORK, descriptionModule briefSummary: To determine and compare the rate and extent of absorption of a test formulation with that of a reference innovator formulation when given as equal labeled dose in healthy subjects under fasting conditions, conditionsModule conditions: Healthy Volunteer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Celecoxib 200 mg capsule, outcomesModule primaryOutcomes measure: Bioequivalence based on Cmax period, primaryOutcomes measure: Bioequivalence based on AUC parameters, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337409, orgStudyIdInfo id: BE24-004, briefTitle: Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2024-07-05, completionDateStruct date: 2024-07-13, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-02, sponsorCollaboratorsModule leadSponsor name: International Bio service, class: NETWORK, descriptionModule briefSummary: To determine and compare the rate and extent of absorption of a test formulation with that of a reference innovator formulation when given as equal labeled dose in healthy subjects under fasting conditions, conditionsModule conditions: Healthy Volunteer, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Generic empagliflozin 25 mg film-coated tablets, outcomesModule primaryOutcomes measure: Bioequivalence based on Cmax period, secondaryOutcomes measure: Bioequivalence based on AUC parameters, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 55 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06337396, orgStudyIdInfo id: 1001, briefTitle: Omic Approaches to Neurodevelopmental Disabilities, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-05-05, primaryCompletionDateStruct date: 2023-07-28, completionDateStruct date: 2023-12-31, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-03-29, sponsorCollaboratorsModule leadSponsor name: IRCCS Eugenio Medea, class: OTHER, descriptionModule briefSummary: to bridge the gap between the molecular structure of CNV and the effect on the phenotype, considering NDDs as complex diseases, as they are a consequence of the imbalance in several dosage-sensitive genes, we might try to approach them through different --omics investigations (genomics, epigenomics, transcriptomics) according to the emerging field of network medicine. This holistic can provide valuable insight into understanding peculiar molecular mechanisms and unsuspected molecular interactions that contribute to the pathogenesis of the condition and possibly pave the way for uncovering new drug strategies that even if they do not heal the patient may improve his performance and the social interaction, conditionsModule conditions: Neurodevelopmental Disorders, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 22, type: ACTUAL, armsInterventionsModule interventions name: WGS and transcriptome analysis, outcomesModule primaryOutcomes measure: Number of likely pathogenic structural variants, primaryOutcomes measure: Number of patients for whom a genotype-phenotype correlation is found, eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 18 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Scientific Institute IRCCS Eugenio Medea, city: Bosisio Parini, state: LC, zip: 23842, country: Italy, geoPoint lat: 45.80075, lon: 9.29, hasResults: False
protocolSection identificationModule nctId: NCT06337383, orgStudyIdInfo id: 12.2021 ANGELMAN, briefTitle: Study of the Prevalence of Autistic Traits in Angelman Syndrome, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-03-15, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-03-29, lastUpdatePostDateStruct date: 2024-04-18, sponsorCollaboratorsModule leadSponsor name: IRCCS Eugenio Medea, class: OTHER, descriptionModule briefSummary: The goal of this observational cross-sectional study is to establish the prevalence of autism spectrum disorder in children and adolescents with Angelman syndrome. The main questions it aims to answer are:* which clinical variables differentiate AS patients with and without Autism Spectrum Disorder between genetics, epilepsy, pharmacotherapy, behavioural problems, parenting style and parents' perceived stress.* which clinical variables differentiate parenting styles and levels of perceived stress.Data from neuropsychological, speech therapy and physiotherapeutic assessments are collected during regular clinical follow-ups, regarding: cognitive development ("Bayely Scales of Infant Development-III", Cognitive Scale) and adaptive behaviour; Autism and Autism Spectrum Disorder ("Autism Diagnostic Observational Schedule-2"); parental stress and parenting styles; social-communicative skills; motor development., conditionsModule conditions: Angelman Syndrome, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 46, type: ESTIMATED, outcomesModule primaryOutcomes measure: Total score of the Autism Diagnostic Observation Schedule -2 (ADOS-2), Module 1,, secondaryOutcomes measure: Age-equivalent score at the Cognitive Scale of the Bayley Scales of Infant Development - 3rd version (Bayley-III), secondaryOutcomes measure: Total Stress score at the Parent Stress Index - 4th edition (PSI-4) questionnaire, secondaryOutcomes measure: Global score at the Aberrant Behaviour Checklist (ABC), secondaryOutcomes measure: Total Raw score at the Social Communication Questionnaire - Current version(SCQ), eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 14 Years, stdAges: CHILD, contactsLocationsModule locations facility: I.R.C.C.S. "E.Medea", status: RECRUITING, city: Conegliano, state: Treviso, zip: 31015, country: Italy, contacts name: Martina Baggio, role: CONTACT, phone: +39 340 802 1282, email: martina.baggio@lanostrafamiglia.it, geoPoint lat: 45.88805, lon: 12.30201, hasResults: False